What the Glycan Route Adds to DAR Design
OBI Pharma's WO2026117757 describes a method for building site-specific antibody-drug conjugates through the conserved N297 glycan region of an antibody. The workflow trims native N-glycans to a core GlcNAc acceptor, installs functionalized sugar donors, and then couples linker-payload units by bioorthogonal chemistry. CHEMOS readers should care because the disclosure frames DAR as a glycan-donor design variable, not only as an outcome of stochastic lysine or cysteine conjugation.
Why the DAR Ladder Matters
Drug-antibody ratio remains one of the central design variables in ADC development. A higher payload count changes how teams evaluate linker-payload loading, conjugate distribution, analytical complexity, and final product consistency. A lower payload count may simplify homogeneity targets but changes payload-per-antibody design assumptions. The practical question is not simply how high DAR can go; it is whether the conjugation chemistry can place payloads predictably enough for a defined product profile.
WO2026117757 uses azide-sugar oxazoline donors to create a DAR range from 2 to 16. The reported arithmetic is simple: the number of azide groups on the installed sugar donor is counted and multiplied by two because an IgG antibody contains two Fc N297 glycan sites. In the reported examples, final ADC assembly is described for DAR2, DAR4, and DAR8. For DAR12 and DAR16, reported data indicate the corresponding azide-sugar oxazoline donors were synthesized, but final ADC assembly was not shown in that article.
That distinction is important for technical reading. The donor chemistry suggests a broader design space, but assembled conjugate data and downstream characterization remain the evidence needed to judge each DAR level as a developable ADC format.
The N297 Glycan as a Conjugation Handle
The reported process starts from the antibody's Fc glycan region rather than from broadly distributed amino acid side chains. Native antibody N-glycans are heterogeneous, so the disclosure uses a preparative glycoengineering step before payload attachment.
In the first step, EndoSz-D234M and EndoH are used for deglycosylation. The goal is to remove most native N-glycan structures at N297 while leaving a single core N-acetylglucosamine, or GlcNAc, as the acceptor site. Reported data show that the two-enzyme approach broadens glycan substrate coverage, including high-mannose glycan forms, and can reach more than 90% to near-complete deglycosylation.
In the second step, a functional sugar donor is installed by transglycosylation. The reported workflow uses EndoSz-D234M again in this role, transferring a prebuilt oxazoline sugar donor carrying an azide or DBCO-compatible handle onto the antibody GlcNAc. This step converts the antibody into a defined intermediate with a designed number of bioorthogonal handles.
The third step is click conjugation between the modified antibody and a linker-payload component bearing the complementary reactive group. In process terms, the chemistry separates glycan remodeling from payload attachment, which can help development teams evaluate donor design, linker choice, payload stoichiometry, and final conjugate quality as linked but separable variables.
Process Questions for ADC Development Teams
For R&D and CDMO teams, the disclosure points to several practical evaluation points.
First, donor design becomes a payload-placement tool. A single glycan donor can encode more than one reactive handle, allowing DAR to be adjusted through the sugar donor structure. That shifts part of DAR control upstream into carbohydrate-linker intermediate design.
Second, enzyme coverage matters. Because antibody glycan populations can vary by cell line, clone, upstream process, and purification history, a dual-enzyme deglycosylation strategy may be relevant when a single endoglycosidase does not process all glycoforms efficiently. In those examples, the enzyme workflow is limited to EndoSz-D234M plus EndoH.
Third, higher DAR formats need careful analytical framing. If DAR12 or DAR16 conjugates are later assembled, analytical work would need to resolve conjugate distribution, residual donor, residual linker-payload, unconjugated antibody, aggregates, and stability under relevant storage and formulation conditions. The patent record does not provide those final ADC data for DAR12 or DAR16, so those formats should be discussed as disclosed donor potential rather than confirmed final products.
Fourth, payload chemistry still needs separate evaluation. A site-specific glycan platform can define attachment position, but linker structure, payload identity, conjugate stability, and final analytical profile still need to be assessed for each design. The patent angle therefore intersects with medicinal chemistry, carbohydrate chemistry, bioorthogonal reaction design, and analytical control.
OBI-902 as Related Platform Context
The patent context also references OBI-902, described as a TROP2-targeted ADC built on the GlycOBI and EndoSymeOBI platform concepts, carrying the TOP1 inhibitor exatecan. For CHEMOS readers, that example is best treated as context for why glycan-directed conjugation is being discussed: the chemistry interest is in how a remodeled Fc glycan can serve as a defined attachment site for linker-payload installation and DAR control.
FAQ
What is glycan-directed ADC conjugation?
It is an ADC conjugation strategy that uses antibody glycans, such as the Fc N297 glycan region, as engineered attachment sites. In the described workflow, native glycans are trimmed, a functional sugar donor is installed, and the linker-payload is attached by click chemistry.
Which DAR values are described in the glycan-directed route?
The reported data show final ADC assembly for DAR2, DAR4, and DAR8. It also reports azide-sugar oxazoline donor synthesis for DAR12 and DAR16, but not final DAR12 or DAR16 ADC molecules.
Why use EndoSz-D234M and EndoH together?
Reported data indicate that the dual-enzyme deglycosylation step broadens substrate coverage across native antibody glycoforms, including high-mannose structures, and leaves a core GlcNAc acceptor at N297.
What is the chemistry relevance for CHEMOS readers?
The disclosure is relevant to ADC linker-payload design, carbohydrate donor synthesis, bioorthogonal conjugation, DAR control, and analytical strategy for site-specific bioconjugates.
References
- Official patent record: WO2026117757 on WIPO PATENTSCOPE